Number 719 • January 2018

Product supply shortages addressed for *Alberta Drug Benefit List* (ADBL)

Alberta Blue Cross has been advised by Actavis Pharma Company and Apotex Inc. that the shortages for Act Olmesartan HCT 40 mg/25 mg Tablet (DIN 02443139) and Apo-Olmesartan/HCTZ 40 mg/25 mg Tablet (DIN 02453622) respectively have been resolved. Due to the long-term nature of these shortages, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **February 19, 2018**.

OLMESARTAN MEDOXOMIL/ HYDROCHLOROTHIAZIDE

40 MG / 25 MG TABLET

00002443139	ACT OLMESARTAN HCT	APH	\$ 0.6038
00002453622	APO-OLMESARTAN/HCTZ	APX	\$ 0.6038
00002319632	OLMETEC PLUS	MFC	\$ 1.0896

Alberta Blue Cross has been advised by Pharmascience Inc. and Glenmark Pharmaceuticals Canada Inc. that the shortages for pms-Ursodiol C 250 mg Tablet (DIN 02273497) and Ursodiol Tablets USP 250 mg Tablet (DIN 02426900) respectively have been resolved. Due to the long-term nature of these shortages, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **February 21, 2018**.

URSODIOL

250 MG TABLET

00002273497	PMS-URSODIOL C	PMS	\$ 0.7636
00002426900	URSODIOL TABLETS USP	GLM	\$ 0.7636
00002238984	URSO	AXC	\$ 1.4735

Alberta Blue Cross has been advised by Pharmascience Inc. that the shortage for pms-Ramipril-HCTZ 10 mg/12.5 mg Tablet (DIN 02342154) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **February 21, 2018**.

RAMIPRIL/ HYDROCHLOROTHIAZIDE

10 MG / 12.5 MG TABLET

00002342154	PMS-RAMIPRIL-HCTZ	PMS	\$ 0.2765
00002283166	ALTACE HCT	VCL	\$ 0.5018

Alberta Blue Cross has been advised by Apotex Inc. and Auro Pharma Inc. that the shortages for Apo-Entecavir 0.5 mg Tablet (DIN 02396955) and Auro-Entecavir 0.5 mg Tablet (DIN 02448777) respectively have been resolved. Due to the long-term nature of these shortages, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **February 22, 2018.**

ENTECAVIR

0.5 MG TABLET

00002396955	APO-ENTECAVIR	APX	\$ 5.5000
00002448777	AURO-ENTECAVIR	AUR	\$ 5.5000
00002430576	PMS-ENTECAVIR	PMS	\$ 5.5000
00002282224	BARACLUDE	BMS	\$ 22.0000

Alberta Blue Cross has been advised by Apotex Inc. and Pharmascience Inc. that the shortages for Apo-Lithium Carbonate 300 mg Capsule (DIN 02242838) and pms-Lithium Carbonate 300 mg Capsule (DIN 02216140) respectively have been resolved. Due to the long-term nature of these shortages, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **February 22, 2018**.

LITHIUM CARBONATE

300 MG CAPSULE

00002242838	APO-LITHIUM CARBONATE	APX	\$ 0.0657
00002216140	PMS-LITHIUM CARBONATE	PMS	\$ 0.0657
00000236683	CARBOLITH	VCL	\$ 0.0964
00002242838	APO-LITHIUM CARBONATE	APX	\$ 0.0657
00000406775	LITHANE	ERF	\$0.1054

When you have questions:

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at:

780-498-8370 (Edmonton and area) • **403-294-4041** (Calgary and area) • **1-800-361-9632** (toll free) **FAX 780-498-8406** (Edmonton and area) • **FAX 1-877-305-9911** (toll free)

Alberta Blue Cross offers online access to current Pharmacy Benefacts and supplemental claiming information to assist with the submission of your direct bill drug claims. **Visit** www.ab.bluecross.ca/providers/pharmacy-home.php



